- Store
- >
- THERAPEUTIC
- >
- QLT091001
QLT091001
SKU:
THE0386
$0.00
Unavailable
per item
10-year Global therapeutic forecast for QLT091001 indicated for Leber Congenital Amaurosis, Retinitis Pigmentosa.
(The treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase) genes and the treatment of retinitis pigmentosa.)
Forecasts are provided by country with sources/methodology explanation. Additional countries can be line-itemed by request. Pricing assumptions, access assumptions, epi literature PDFs and other source files will be provided in addition to the forecast.
SUBSCRIBERS: Click Buy Now and your subscription will be recognized by your email address.
NON-SUBSCRIBERS: Click Buy Now and enter your contact information to set up a consultation or to request one free standard report for first-time customers. No payment information is required. We will contact you within 12 hours.
ADVANCED patient subtyping and landscape analyses are also available, as well as KOL research and other approaches. For advanced analyses, begin by requesting this standard therapeutic forecast (click Buy Now) and we will contact you within 12 hours. Alternately, directly contact [email protected] (or your account manager) to connect on needs and timing.
(The treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase) genes and the treatment of retinitis pigmentosa.)
Forecasts are provided by country with sources/methodology explanation. Additional countries can be line-itemed by request. Pricing assumptions, access assumptions, epi literature PDFs and other source files will be provided in addition to the forecast.
SUBSCRIBERS: Click Buy Now and your subscription will be recognized by your email address.
NON-SUBSCRIBERS: Click Buy Now and enter your contact information to set up a consultation or to request one free standard report for first-time customers. No payment information is required. We will contact you within 12 hours.
ADVANCED patient subtyping and landscape analyses are also available, as well as KOL research and other approaches. For advanced analyses, begin by requesting this standard therapeutic forecast (click Buy Now) and we will contact you within 12 hours. Alternately, directly contact [email protected] (or your account manager) to connect on needs and timing.